3-Step treatment efficient for small pupils

Article

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm undergoing femtosecond laser-assisted cataract surgery.

The study, led by Dr Ina Conrad-Hengerer (Center for Vision Science, Ruhr University Eye Hospital, Bochum, Germany), examined eyes with an intraoperative pupil size smaller than 5.5 mm to evaluate the efficacy of a 3-step treatment to achieve larger pupil sizes before femtosecond laser-assisted cataract surgery. This 3-step process consisted of initially administering intracameral epinephrine solution, then using additional viscomydriasis and thirdly implantation of a Malyugin ring pupil expander.

Out of 850 eyes that were scheduled to receive cataract surgery, 40 underwent the sequential treatments for pupil expansion. Of this group, 7% only required the first step to achieve a pupil size larger than 5.5 mm, 25% required additional voscomydriasis and 68% needed the pupil expander as well. The team found that the most frequent comorbidities were pseudoexfoliation of the lens capsule (30%) and intraoperative floppy-iris syndrome (12.5%).

Based on this study, it was deemed that the 3-step treatment allowed an increased efficiency and safety of femtosecond laser-assisted cataract surgery in eyes with a small pre-op pupil size.

For more detailed information please view the abstract from the Journal of Cataract & Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.